Trial Profile
Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the Integrase Inhibitor Raltegravir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms RACING
- Sponsors Merck & Co; Merck Sharp & Dohme
- 01 Jan 2017 Results (n=221) assessing QoL outcomes in patients treated with raltegravir, published in the HIV Clinical Trials
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.